| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Cyclopamine | GDSC1000 | pan-cancer | AAC | -0.051 | 0.3 |
| mRNA | Axitinib | FIMM | pan-cancer | AAC | -0.15 | 0.3 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | -0.043 | 0.3 |
| mRNA | XMD15-27 | GDSC1000 | pan-cancer | AAC | -0.033 | 0.3 |
| mRNA | Pyrimethamine | GDSC1000 | pan-cancer | AAC | -0.05 | 0.3 |
| mRNA | N9-isopropylolomoucine | CTRPv2 | pan-cancer | AAC | 0.035 | 0.3 |
| mRNA | Tipifarnib | FIMM | pan-cancer | AAC | -0.12 | 0.3 |
| mRNA | FMK | GDSC1000 | pan-cancer | AAC | -0.035 | 0.3 |
| mRNA | SNX-2112:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.032 | 0.3 |
| mRNA | Midostaurin | GDSC1000 | pan-cancer | AAC | 0.032 | 0.3 |